First May PBS listing goes to...

Posted 1 May 2026 AM

Takeda’s “ongoing investment in oncology” has paid off with the PBS listing of anti-VEGF agent Fruzaqla, according to the company’s Oceania General Manager, Dave Pearce.

The Japanese pharma first submitted Fruzaqla to the PBAC’s July 2024 meeting, however as the drug was still awaiting the TGA’s approval, it was pushed into the September intracycle meeting at which it was recommended for PBS listing.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here